Oren Langer Named a 2023 Emerging Therapies/Life Sciences Trailblazer by The National Law Journal
July 5, 2023
Robins Kaplan LLP is pleased to announce that Oren Langer has been selected to The National Law Journal’s list of Emerging Therapies/Life Sciences Trailblazers. This list recognizes attorneys who “have made significant marks on the practice, policy and technological advancements in their sector.”
Langer serves as Managing Partner of the firm’s New York office. An accomplished patent litigator, he has worked extensively under the Hatch-Waxman regulatory framework. He’s examined and cross-examined fact and expert witnesses at nearly one dozen trials, representing a variety of clients, including Collegium Pharmaceutical, Inc., Amneal Pharmaceuticals, Inc., Hikma Pharmaceuticals USA, Inc., Torrent Pharmaceuticals Ltd., and Novel Labs. In 2022, among other accolades, Langer was named a recommended litigator in the IAM Patent 1000 and a “Life Sciences Star” by LMG Life Sciences.
Langer is the co-creator, principal editor, and contributor of the firm’s Hatch-Waxman Litigation quarterly newsletter, GENERICally Speaking, which reports on recently filed ANDA lawsuits, ANDA approvals, generic drug launches, relevant settlements, and case blurbs on meaningful court decisions. He has been named a Top Author by JD Supra for six consecutive years for his contributions to this publication.
View Langer’s profile in The National Law Journal here.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.